Drug Database
Back to search

Netherlands· NL-d0577ab6f0a5

Emblaveo 1,5 g/0,5 g poeder voor concentraat voor oplossing voor infusie

A aztreonam und beta-lactamase-inhibitor product containing avibactam natrium 0-water + aztreonam, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 7 of our 19 countries.

ATC J01DF51

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEmblaveo 1,5 g/0,5 g poeder voor conc…ATCJ01DF51REGISTER NO.NL-d0577ab6f0a5PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about avibactam natrium 0-water + aztreonamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aztreonam und beta-lactamase-inhibitor is registered in 7 of 19 countries.

Countries holding a registration under ATC J01DF51 (aztreonam und beta-lactamase-inhibitor), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose
Search aztreonam und beta-lactamase-inhibitor products by name

Aztreonam und beta-lactamase-inhibitor · ATC J01DF51

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
AVIBACTAM NATRIUM 0-WATER + AZTREONAM
Manufacturer
Pfizer Europe MA EEIG
Country
Netherlands (NL)
ATC code
J01DF51
ATC class
Aztreonam und Beta-Lactamase-Inhibitor
Defined daily dose
6 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/24/1808

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Aztreonam und beta-lactamase-inhibitor in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aztreonam und beta-lactamase-inhibitor products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Emblaveo
  • Liechtenstein · Emblaveo
  • Norway · Emblaveo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/58385b15-67a7-4dd2-941a-02f6f449de64
GET /v1/drugs/58385b15-67a7-4dd2-941a-02f6f449de64?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/emblaveo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Aztreonam and beta-lactamase inhibitor",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132180",
  "excipients": [
    "ARGININE, (L-)",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "AVIBACTAM NATRIUM 0-WATER",
    "AZTREONAM"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/04/22",
  "procedure_number": "EMEA/H/C/006113",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1808",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about aztreonam und beta-lactamase-inhibitor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console